Nkarta reports moderate or major responses in 5 of 6 myositis patients in NKX019 trial
NKTX•Nkarta said 5 of 6 myositis patients had moderate or major responses in its NKX019 trial. Across 40 patients, the company reported no deaths, adverse-event-related treatment discontinuations or immune effector cell-associated toxicities.
1. Initial trial results
Nkarta announced initial NKX019 trial results showing clinical improvement in most evaluable patients with treatment-resistant myositis or systemic sclerosis. Myositis responses included improved muscle strength, while systemic sclerosis patients showed rapid reductions in skin thickening.
2. Safety and next steps
Across 40 patients, Nkarta reported no deaths, treatment discontinuations due to adverse events or immune effector cell-associated toxicities. Additional integrated safety data will be presented November 11, and the company plans FDA discussions on potential registrational pathways. Further follow-up results and a registrational dose-selection plan are expected in the first half of 2027.
